<DOC>
	<DOC>NCT01029132</DOC>
	<brief_summary>To investigate the characteristics of treatment responders to galantamine.</brief_summary>
	<brief_title>Characteristics of Treatment Responders to Galantamine</brief_title>
	<detailed_description>The purposes of this study are: 1. to investigate the characteristics of treatment responders to galantamine by examining the clinical response of galantamine in patients with mild to moderate AD for 52 weeks. 2. to examine the specific cognitive sub-domains that are more sensitive to galantamine administration.</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>1. A diagnosis of probable AD according to the criteria of the NINCDSADRDA 2. Korean version MiniMental State Examination scores between 10 and 26 3. History of cognitive decline that had been gradual in onset and progressive over at least 6 months 4. A caregiver who could assist the patient with medication, attend the assessment and provide information about the patient. 1. they had evidence of any neurodegenerative diseases other than AD (i.e. Parkinson's disease, Huntington's disease) 2. Psychiatric disorder or severe behavioral disturbances that required psychotropic medications 3. Cerebral injuries induced by trauma, hypoxia, and/or ischemia 4. Clinically active cerebrovascular disease; History of seizure disorder 5. Other physical conditions that required acute treatment.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Alzheimer's disease</keyword>
	<keyword>Galantamine</keyword>
	<keyword>Treatment response</keyword>
	<keyword>Efficacy</keyword>
	<keyword>Adverse Event</keyword>
</DOC>